The FDA has granted fast-track approval to the drug telisotuzumab vedotin (sold as Emrelis) as a first-of-its-kind treatment for certain people who have non-squamous non-small-cell lung cancer.

Almost a third of Americans are more than a year behind in cancer screening, more than half of them because of out-of-pocket ...

For patients with EGFR-mutated NSCLC, treatment options in the frontline include osimertinib monotherapy, amivantamab with ...

CURE provides access to the cancer news, latest oncology research & expert insights that serve as a guide to every stage of the cancer experience.

Zongertinib conferred a clinically meaningful benefit in patients with previously treated, advanced, HER2-mutant NSCLC in a phase 1 trial.

MSD has reported that the Phase III KEYNOTE-B96 trial of Keytruda plus paclitaxel, with or without bevacizumab, has met its ...

The latecomer PD-1 inhibitor – already approved for Merkel cell carcinoma – has become the first cancer immunotherapy for ...

Recent phase 2 data support combination treatment with samuraciclib for those with HR+ advanced breast cancer following prior ...

Discover 9 promising small molecule drug discovery companies that recently raised funding for their potentially breakthrough ...

NVO to Co-Develop Septerna’s Oral Therapies for Obesity/Diabetes. Novo Nordisk signed a licensing deal with Septerna to co ...

Get our top picks of the posters at AACR 2025 and learn more about the method behind them and the techniques used.

Brainomix, a company pioneering AI-powered imaging solutions in lung fibrosis and stroke, will be presenting new evidence next week at the American Thoracic Society (ATS) Conference in San Francisco ...